Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.585 USD | -0.45% | +26.21% | -36.96% |
Apr. 29 | Prime Medicine Shares Jump After Application for Chronic Granulomatous Disease Treatment Gets FDA Clearance | MT |
Apr. 29 | Prime Medicine Gets FDA Clearance for PM359 IND Application | DJ |
Financials (USD)
Sales 2024 * | 12.62M | Sales 2025 * | 12.61M | Capitalization | 647M |
---|---|---|---|---|---|
Net income 2024 * | -218M | Net income 2025 * | -223M | EV / Sales 2024 * | 42.6 x |
Net cash position 2024 * | 109M | Net cash position 2025 * | 275M | EV / Sales 2025 * | 29.4 x |
P/E ratio 2024 * |
-3.04
x | P/E ratio 2025 * |
-3.46
x | Employees | 234 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.06% |
Latest transcript on Prime Medicine, Inc.
1 day | +6.45% | ||
1 week | +30.47% | ||
Current month | +14.02% | ||
1 month | -11.23% | ||
3 months | -15.13% | ||
6 months | -15.38% | ||
Current year | -36.68% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 70 | 20-06-30 | |
Allan Reine
DFI | Director of Finance/CFO | 49 | Jan. 16 |
Chief Operating Officer | 52 | 22-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 64 | 21-11-30 | |
Robert Nelsen
BRD | Director/Board Member | 60 | 20-08-31 |
Michael Kelly
BRD | Director/Board Member | 67 | 21-10-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.71% | 2 M€ | -25.75% | ||
0.00% | 9 M€ | +5.77% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 5.585 | -0.45% | 541 591 |
24-05-02 | 5.61 | +6.45% | 852,030 |
24-05-01 | 5.27 | +7.11% | 815,155 |
24-04-30 | 4.92 | +1.23% | 1,203,190 |
24-04-29 | 4.86 | +9.83% | 1,268,471 |
Delayed Quote Nasdaq, May 02, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.68% | 647M | |
-1.65% | 103B | |
+6.75% | 101B | |
+6.40% | 23.07B | |
-12.60% | 22.23B | |
-5.24% | 18.05B | |
-39.98% | 17.18B | |
-10.17% | 16.94B | |
+6.12% | 14.07B | |
+35.47% | 12.35B |
- Stock Market
- Equities
- PRME Stock